Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/303% below fair value
$33.79−0.71 (-2.06%)
Close on Nov 13, 2026Market cap $1.03BP/E –Yield 0.00%
Castle Biosciences enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Castle Biosciences's enterprise value was $780.26M on Nov 11, 2026, against $887.52M a year earlier. Over the last 5 years it ranged from $134.08M to $887.52M, with a median of $412.43M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $780.26M | -8.9% |
| 2025 | Dec 31, 2025 | $856.90M | +80.1% |
| 2024 | Dec 31, 2024 | $475.79M | +35.7% |
| 2023 | Dec 29, 2023 | $350.54M | -1.1% |
| 2022 | Dec 30, 2022 | $354.31M | -50.8% |
| 2021 | Dec 31, 2021 | $720.86M | -38.5% |
| 2020 | Dec 31, 2020 | $1.17B | +126.6% |
| 2019 | Dec 31, 2019 | $517.26M | – |
See a number that looks wrong?